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Statement of Work 
Executive Summary 
Every three minutes, a person is committed to the emergency room as a result of a food allergy 
in the United States. Over the period of a year, roughly 200,000 people require medical 
attention for these severe allergic reactions as a result of anaphylaxis [1]. Anaphylaxis (also 
known as anaphylactic shock) causes your immune system to release a flood of chemical 
substances, including histamine from cells in the blood and tissues where they are stored. 
These released chemicals are caused by the interaction between an allergic antibody 
Immunoglobulin E (IgE) and the substance (allergen) causing anaphylactic shock [2]. Where 
even trace amounts of the allergen can cause a reaction of hives, swelling, and lowered blood 
pressure. The immediate treatment of anaphylactic shock consists of epinephrine typically 
delivered by an auto-injector. The most common adrenaline auto-injector is the EpiPen by 
Mylan which was prescribed to an estimated 3.6 million Americans in 2015 [7]. The price of an 
EpiPen is around $650 for a two-pack which has gone up from $93.88 from 2007 of an increase 
of 500%. Due to the dramatic price increase, many consumers are forced to hold onto their 
expired EpiPens at risk of anaphylactic shock as they can not afford a new prescription. As a 
result, the purpose of our senior design project is to create an affordable alternative to the 
EpiPen that will act as an acceptable generic in the current market. 
Introduction 
Project: Alternative Epinephrine Injector started as a solution for Bianca Aleman’s little brother 
however the scope has evolved to include the many millions of individuals across the world who 
struggle with a life-threatening allergen. The stakeholders of this project are Cal Poly and Dr. 
Michael D. Whitt. Our goals are the following: 
● Develop a foolproof method of injection that consistently delivers a dosage of 
epinephrine  
● Be equal or less than the current size of an EpiPen (6 in) 
● Be easy to transport or store when not-in-use 
● Create an isolated environment where the epinephrine will not be denatured due to 
environmental changes (e.g. temperature, light sensitivity, etc.) 
● Class II FDA Medical Device 
● Deliver a fully functioning prototype of an alternative epinephrine auto-injector  
● Stay within a budget of $200 - $700 
● Do not infringe on Mylan or Kaleo’s current patent 
Background 
Patients who suffer from severe allergic reactions causing anaphylaxis utilize the medication 
epinephrine, via a subcutaneous injection, to improve their symptoms and reverse swelling in 
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the throat to open up breathing. Currently, Mylan’s EpiPen Auto-Injectors and EpiPen Jr. nearly 
corner the market for epinephrine injection products. These Mylan products, for non-insured 
individuals, can cost between $300 and $630, which is a 500 percent price increase since 2007 
[6]. Other companies have released similar products, the Adrenaclick, Auvi-Q, and Symjepi, as 
well as some generic name products, but all of which are still highly expensive (the cheapest 
priced at $110, without insurance). From our research, we found a new product would impact a 
large market, with 32 million Americans suffering from food allergies, 200,00 of which requiring 
emergency medical care, and most of which being highly dissatisfied with the current options 
available for treatment [1]. 
 
Anaphylaxis is a life-threatening condition, brought on by serious allergic reactions. At-risk 
patients are typically prescribed epinephrine auto-injectors; however a large proportion of 
patients fail to fill their prescriptions due to high prices, which is due to the lack of regulations on 
price, given it is not classified as a preventative medicine [8]. Lack of patient adherence is a 
serious concern, as prompt facilitation of the medication is necessary for reducing 
hospitalizations and fatalities [3]. While the benefits of using epinephrine auto-injectors highly 
outweighs the risks, it is important to note them. When using auto-injectors, specifically when 
used by children, accidental injections of epinephrine to people not in anaphylactic shock have 
been known to occur, which requires medical attention due to the possibility of tissue death due 
to blood flow reduction. As well, many patients use expired devices due to their high cost. While 
some risks are associated with this practice, they are still effective and do not induce a higher 
risk [6]. 
 
A study performed on the importance of usability of auto-injectors as treatment for anaphylaxis 
showed that EpiPen Jr.’s were inferior to the design of the Auvi-Q [5]. The Auvi-Q, produced by 
Kaleo, is shaped more closely to a small box compared to the EpiPen Jr.’s near cylindrical, 
pen-shaped design. This study was evaluated by studying untrained adults’ completion of 
injection tasks on child-sized mannequins, and showed a far higher rate of accidental injection 
(if needle had not been removed) when using the EpiPen Jr. and the when using the Auvi-Q, a 
much higher rate of injection into the desired region was found. 
 
Table 1. Current products on the market 
Patent # Potential Infringements 
10,406,288 The specific parts in which comprises the delivery mechanism for an 
auto-injector. The delivery mechanism’s drive members. 
10,320,439 Utilizing a smartphone case as a housing for an epinephrine auto-injector 
10,369,292 The plunger assembly for a fluid dispensing syringe, such as the one in an 
auto-injector 
10,525,206 The creation of an auto-injector that is not sufficiently unique from this 
definition. 
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10,500,337 The creation of an auto-injector utilizing a piston that is not sufficiently 
different from this definition. 
 
This device would most likely be classified as a class II device, per the FDA regulations for 
medical devices. With this classification, to move to the market, the most critical regulation 
would be the 21 CFR, most specifically the 21 CFR part 807 - the Pre-Market Notification 
510(k). Once a prototype is developed, it may go into clinical trials in laboratory environments. 
Next, it must be submitted for a pre-market notification to get FDA clearance. Once approval is 
received, the device must stay in compliance for its lifetime. 
Objectives 
Problem Statement 
● Develop and deliver an alternative epinephrine injector suitable as a replacement for the 
market’s leading medical device. 
 
Boundary Definition 
● Explicitly includes: 
○ Alternative epinephrine injector 
○ Auto-injection mechanism 
○ Safety mechanism 
○ Isolated environmental chamber 
■ Resists temperature fluctuations 
■ Reduces exposure to light  
● Explicitly does not include: 
○ Infringement on current Mylan EpiPen patent or Kaleo Auvi-Q 
■ Mylan: US Patent No. 7,794,432 
■ Kaleo: US Patent No. 8,920,377 
 
Summary of Customer Needs/Wants 
● From information received in needs assessments with actual consumers, we found the 
customers need a highly reliable and safe epinephrine auto-injector for use during 
life-threatening anaphylactic shock.  
● As well, we found customers wanted an alternative to the current market leaders 
(EpiPen and Auvi-Q), in that they want a device that is smaller, more user-friendly, and 
cheaper. 
 
Product Specifications Matrix 
● See ‘House of Quality’ document for in-depth analysis. 
 
Specification Measurement 
● See ‘Specification Development’ on page 13. 
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High-Risk Specifications  
● The high-risk specification we face is the injection mechanism as a drug auto-injector is 
considered a class II medical device. 
Project Managemen​t 
The first stage of the design process is to create and identify how the auto-injector will deliver 
the epinephrine into the subject. After the mechanism is designed, the environmental isolation 
chamber which houses the epinephrine will need to be created as it will house and protect the 
drug from potential environmental factors. Then, we can create a housing for both subunits 
which covers the delivery mechanism and environmental chamber. 
 
The project timeline and critical path will be delivered at a later date after the second revision of 
our network diagram has been completed. 
 
Special analysis techniques will be reviewed later as we approach a prototype. 
Conclusion 
The purpose of this statement of work is to finalize and confirm our project’s scope, explain the 
background and market need for a new product, and detail our design process. In the coming 
weeks, a shortlist of potential final design concepts can be expected. We ultimately plan to have 
completed our research and design specifications by 2/18 and our final prototype design by 3/9. 
Our written documentation of our product will be finalized by 3/15 so we can present our critical 
design report on 3/16. We plan on using the rest of our time to manufacture, test, and finalize 
our product as to have a design review poster presentation during the senior project exposition 
by 6/6. Throughout the process we will strive to reach all of our deliverables on time while 

















Figure 1a. Network Diagram including Critical and Non-Critical Tasks 
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Figure 1b. Network Diagram and Critical Path  
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Indications for Use 
Our product is indicated for the relief of symptoms in patients who are experiencing 
life-threatening anaphylactic shock due to consumption or exposure to allergens or any other 
known or unknown triggers as judged by the patient themselves. The intended use of this 
product is for immediate emergency procedure only. Further medical help should be sought and 






Our materials list for our budget is a living document that we will make alterations to as we 
continue this project. Currently, our total project budget is $700; however, we aim to stay well 
below this amount. It is presumed that the main allocation of our budget will be to 3D printing 
materials to design the casing/housing of our auto-injector. The amount of filament needed may 
fluctuate due to how many prototypes are printed. 
 










In order to define our customer requirements, we interviewed current carriers of similar 
products, EpiPen and Auvi-Q, to determine what features of an auto-injection device were 
necessary for our product. The customer requirements were portability, production cost, and 
ease of use.  
 





2. Production Cost 
a. Material Composition 
b. Method of Manufacturing 
c. Complexity of Device 
3. Ease of Use 
a. Design Efficiency 








Before applying quantitative measurements to each of our customer requirements, we must first 
define our specifications.  
 
Shape​ - The two most seemingly desirable shapes are a cylindrical shape and a rectangular 
box shape. 
 
Weight​: Our product must not exceed .15 pounds. 
 
Dimensions​- No larger than 3.4” x 2.3” x .5” for a rectangular box design. No larger than R.5” x 
7” for a cylindrical design.  
 
Material Composition: ​3D-printing filament, adhesive, plastic, stainless steel, and glass. 
Additional materials may be incorporated with further manufacturing. 
 
Method of Manufacturing:​ The current method of manufacturing is to 3D-print a designed 
apparatus shell to house the internal components of our device. The first devices will then be 
assembled by hand.  
 
Complexity of Device​: To be reviewed. 
 
Design Efficiency:​ Yield at least four products with the current budget provided. 
 
Design Efficacy:​ Full dosage of medicine should be administered 100% of the time used.  
 






TAM and Competitive Advantage 
In the United States, 3.6 million people are prescribed EpiPens, and 300,000 emergency room 
visits are reported per year for children under the age of 18 due to food allergies [8]. In 2018, 
the U.S. market for EpiPens alone reached approximately US $750 million per year, and the 
entire epinephrine auto-injector worldwide market is estimated to reach US $2.4 billion per year 
by 2024 [4]. The Total Available Market for our product, if 100% of the available market is 
achieved, would be equal to the worldwide market, and thus be very vast.  
 
Our competitive advantage over the two top-selling epinephrine auto-injectors includes our 
product having a less bulky, more user-friendly, and more practical design. As well, while Mylan 
(the owner of the EpiPen brand) had a near monopoly on the market and thus continuously 
increased their prices, we would pledge to not flagrantly pad our profit margins at the expense 
of patients' ability to have access to the product. While it would take time to switch lifetime users 
of EpiPens and Auvi-Qs over to our product, we believe all users who struggle to afford the 
highly expensive auto-injectors would make an immediate switch.  
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Intellectual Property Assessment 
In order to not infringe on any pre-existing patents regarding the design of our auto-injection 
device, it is important to be knowledgeable of exactly what patents are currently on the market. 
Below in Table 2 is a list of three current patents and three patent applications which have some 
claims which we could have potentially infringed upon had we not known them.  
 
Table 2: List of patents and current claims on the market. 







10,406,288 P Dual drive injection 
mechanism wherein 
two drives are 
configured to each 
load their own 
mechanism to 1) 
drive the needle into 
the leg and 2) drive 




a three drive 
composition or a 
way to manufacture 
two components to 
be driven by the 
same mechanism.  
Medical Device 
Case 
10,320,439 P A two pocket 
smartphone case 
where an epinephrine 
injection mechanism 
can be easily 
inserted into one and 
medication tablets 
can be stored within 
the other.  
Either do not 
incorporate a 
smartphone case 
into our design or 
instead make the 
auto injector 
inseparable from the 
phone case.  
Syringe plunger 
assemblies 
10,369,292 P A specific  design for 
an integrated plunger 
and plunger rod 
which can propel 
fluid as well as a 
stopping mechanism 
for the plunger itself. 
Do not incorporate 
this plunger design 
within our device.  
Autoinjector 
carrier 
 20190381236 A A certain housing 
design for an 
autoinjector within 
which the 
autoinjector can be 
easily removed via 
pushing up from the 
bottom. 
Design a different 
housing case for our 
product. Perhaps 
one that uses the 
force of gravity to 
slide our device out 





20190374714 A  ​A method, 
comprising: 
maintaining a needle 
driver of a needle 
actuator under load 
of a spring by mating 
a first key with a first 
notch in the needle 
Design our product 
with a manual 
stimulation 
necessary for 
needle release.  
16 
driver and mating a 
second key with a 
second notch in the 
needle driver; and 
deploying a needle 
coupled to the needle 







20180078710 A A medication 
delivery device 
comprising of a 
syringe, flange, 
syringe barrel, and 
plunger. 
Inhibit the 
withdrawal of blood 
via the needle 
during its removal 









Table with your Factors and Levels 
Factor Level 1 Level 2 




3.37” x 2.125” x .5” 
Cylinder 
R .5” x 6” 
Injection Mechanism Gas-powered Spring-powered 
 
Listing of Conjoint Cards 




1 $360 Cube 
3.37” x 2.125” x 0.5” 
Gas-powered 
2 $360 Cylinder 
R .5” x 6” 
Spring-powered 
3 $650 Cube 
3.37” x 2.125” x 0.5” 
Spring-powered 
4 $650 Cylinder 




Card # Cost Dimensions Delivery 
Mechanism 
1 0 0 0 
2 0 1 1 
3 1 0 1 












Statistical Analysis  
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A brief discussion on which factors you believe will be important to the success of this product 
based on the information obtained from your classmates. 
a.​       ​Which factors matter to my customer (at given confidence). 
As the p-values are greater than .05, we fail to reject the null hypothesis indicating that 
the result is statistically insignificant. 
b.     ​ ​How much those factors affect my customer attraction to using my product (via the 
coefficients given). 
Both cost and dimensions affect our customer attraction equally at a coefficient of .333 
each. However, the method of injection mattered the least to our customers with a 
coefficient of .111. 
c.      How much those factors that matter explain the customer attraction (via r-squared or 
coefficient of determination) 
As our r-squared value is .047, this indicates that there is a very weak 3relationship 











The front runner design we decided upon is a single spring injection mechanism with a button 
actuator that would deliver the epinephrine into the patient. The injection mechanism delivers 
the drug through means of a compressed spring that is coiled around the plunger and held in 
place by the slightly wider top of the plunger which is then released when the button is pressed. 
After the button has been pressed, the needle is then propelled forward as a result of the spring 
force within the device and plunges itself into the patient. As the needle pierces the skin, a 
rubber stopper slides backward revealing the injection hole. Once the injection hole has been 
exposed, the drug is then injected into the patient as a result of the driving rod that pushes the 
rubber stopper forward in the direction of the patient and thus driving the drug into the patient. 
 
The model we have developed relies on the following equation for the force needed to inject the 
solution (epinephrine) into the patient: 





○ F = force required to inject the volume of a solution 
○  = viscosity of the solutionμ  
○ L = length of the needle 
○ D = inner diameter of the syringe’s barrel 
○ d = inner diameter of the needle 
○ V = volume of the solution  
○ T = duration of time  
 
 
This equation will assist us in determining the proper spring constant we need, and thus, the 
spring we will utilize in our design. The needle selected is 1.5 millimeters in diameter, and it is 
hypothesized that the exposed needle length will be approximately 16 millimeters. The diameter 
of the barrel is 11 millimeters. A common concentration for epinephrine in solution is 1mg/1mL. 
With the auto-injectors, even though 2mL of solution is stored, only 0.3 mL, and thus 0.3 mg of 
epinephrine, are actually injected. Each 0.3 mL of solution contains 0.3 mg epinephrine, 1.8 mg 
sodium chloride, 0.5 mg sodium metabisulfite, hydrochloric acid to adjust pH, and water for 
injection. The pH range is 2.2 - 5.0.  
 
The solution, if produced commercially, would be compressed with nitrogen to avoid oxidation, 




The following CAD drawing models our design: 
 
 
In developing the model, we determined that a double-spring epinephrine auto-injector would be 
more complicated and introduced more modes of failure than a single-spring auto-injector. 
Furthermore, in looking at the inspirations of different designs, it was made more apparent that 
the Auvi-Q auto-injector would be more difficult to model as well due to the shape of the 
auto-injector. A credit card-sized injector is much more compact of a design than a linear model. 
The linear model can be most accurately related to that of an EpiPen or an AdrenaClick. 
 
Further development would be impacted by the design/product that makes up the needle and 




The following CAD assembly drawing shows further improvements upon our conceptual model: 
 
 
Our design is made up of five main parts – the outer cylinder case, the button/locking 
mechanism, the inner cylinder guard, the syringe, and the springs. Seen first here is the outer 
cylinder case. This is one of our 3D printed parts and serves as a protective casing for the 
auto-injector, as well as holds the button firmly in place. This piece is the largest of all of the 
parts. The next part is the button/locking mechanism. When in place, the button sticks through a 
hole in the top of the outer casing, while the “legs” attach to the pegs on the syringe. The legs 
serve as a locking mechanism. When the button is depressed, the legs pan out slightly, 
releasing the syringe from being “locked”. The inner cylinder guard is seen below, which 
prevents the button from moving. Both the guard and the button will be 3D printed. The syringe 
will be purchased, along with a needle. We will affix the pegs onto the syringe. Through 
displacement of the spring a small amount of pressurized oxygen will be engaged to push on 
the distal end of the drug compartment, pushing the drug through the needle and into the 
patient. The needle will need to be manually removed from the leg. Lastly, compressed springs 
not seen in this model are to be affixed to the back sides of both the syringe and the button, 
which will provide the force necessary to puncture the skin. When the button releases the 
syringe, the spring is capable of forcing the syringe to its full length which allows the needle to 
be exposed, then forces the oxygen to push the drug out of the syringe. Small changes to the 
overall design of our product can be made as we move forwards with the testing of our project, 
but the overall function or our auto-injection device will remain the same.  
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Prototype Manufacturing Plans 
We hoped to begin our manufacturing in early April, but due to the COVID-19 crisis, we were 
forced to change our project into a more formal research project, developing future 
manufacturing and testing plans for the product. The majority of our prototype will be 3D-printed 
based off of the solidworks designs which we have made. The parts manufactured in this way 
will be the outer cylinder case, inner cylinder guard, the safety cap and the button/locking 
mechanism. A series of springs and glue will be purchased to combine and assemble each of 
the pieces of our device into one cohesive product. The actual needle and syringe of our 
auto-injector is being purchased from a vendor and will be inserted within our device.  
 
Our prior plan was that once we had manufactured our first prototype, we would test our product 
for design flaws and failures. Upon reflection, the details of our design might change, but the 
method of manufacturing will remain the same, 3D-print or purchase the parts that we need. 













Design of Experiments  
We plan on testing our product in three key areas of the design: the needle, the syringe, and the 
efficacy of the device. The first and most important test that we will perform will be to determine 
the strength and failure points of the needle that we are using. Using the provided bend-stress 
testing and shear stress equipment we plan on testing the limits which our needle can 
experience before failure. This is important as we need to know if there will be any danger of the 
needle shearing or bending upon insertion of the leg as that could lead to failure of medicine 
injection or increased physical injury.  
 
Our syringe portion will be tested by submerging the body of the syringe underwater. The 
syringe should be air-tight, as it needs to hold pressurized air within it for a pressure gradient to 
be used for administering our medication. If we see air bubbles leak from our syringe then we 
know we will need to find a different syringe body to use.  
 
The next test we are going to perform is to validate the effectiveness of our device as a whole. 
We are planning on purchasing ballistic gel and testing our completed model on the gel. When 
we can consistently achieve the correct drug dosage and ejection mechanism function then we 
will be ready to submit a final product. An aqueous solution will be mixed to the same viscosity 
as epinephrine during these tests as that will most closely model real life function.  
Performance Metrics 
● Needle 
○ Flex testing 
● Syringe Body 
○ Air-tight sealing 
● Device Efficacy 
○ Delivers full dosage 100% of the time 
 
 Pass Criteria Fail Criteria 
Needle Testing Elastic modulus of 8 +/- .001 
GPa 
Elastic Modulus of 8 +/- .002 
GPa 
Syringe Body No liquid found within the 
syringe body 
Liquid found within the 
syringe body 
Device Efficacy Delivers 100% of dosage 
found within the syringe body 





A sample size of 30 samples, n = 30, will be used for every study.  
Expected Results 
In the three-bend-test, we expect every needle to perform within the given passing parameters. 
As each needle is made from the same material and size, there would be no difference in this 
first test. In the second test, we hope that the syringe body is completely sealed off from the 
surrounding environment. As the syringe bodies are bought from a qualified medical supplier, 
we expect each body to pass. The hardest test we expect to pass is that of device efficacy. As 
our fail criteria includes any remaining liquid within the chamber, if any remains, we would have 
to rethink our design and conduct a revision. We hope for a passing rate greater than 95%. 













Conclusion and Discussion 
 
Current injection-based methods for epinephrine delivery have been proven to be costly, bulky, 
and frequently improperly used, which showcases the deep need and market for a new method 
of epinephrine delivery - a spring powered, button operated auto-injector. Using concept 
morphology and conjoint analysis coupled with a detailed array of customer requirements, our 
team developed a final detailed 3D computer aided design to present to our peers and to our 
stakeholders. Our design, while not sleeker than the most popularized device, the EpiPen, 
would allow for a safer drug delivery mechanism by deferring accidental ‘sticks’ and reducing 
the costs of manufacturing once in the mass production stage due to the simplicity of the 
design. From our research, while the size of the injector was important to the patients, they 
cared more highly about the safety and efficacy of the delivery method; therefore, it became our 
chief point of improvement we wanted to hit. 
 
Due to the ongoing COVID-19 crisis, after the presentation of our detailed designs, we had to 
segway our aims for this project from creating a functional prototype to developing future 
manufacturing and testing plans, all while compiling the information and data into a mock design 
history file, given that we would no longer be able to 3D print our product, and thus hindering us 
from producing a prototype. With that being said, the extra time available due to not spending 
weeks creating a physical deliverable allowed us to develop a far more in-depth understanding 
and explanation of the necessity, purpose, and desired outcomes of our future testing methods 
we would use for a product. As well, the dramatic shift in focus of our project taught us hands-on 
skills for overcoming massive setbacks in engineering settings. 
 
We are confident that patients’ outcomes would increase positively, improper dosings would 
decrease, and more non-patients would feel comfortable using our product compared to the top 
competitors if our product was manufactured in the methods we proposed for future 
manufacturing plans. Our current largest concern is ensuring the needle can be punctured even 
through the thickest of clothing, but with an increase in gauge size of the needle and higher 
spring constant, this can be established, Further clinical studies would be required to prove this, 
but given our presumptions, product specifications, and testing, all of these goals are well within 
reach. We wish we could have seen our design come into physical fruition; however, the 
assurance we received from our research led us to feel wholeheartedly comfortable and in 
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